Amgen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

31.07.13	After-market Movers For July 30 (SYMC, AMGN, TTWO, CBST, QCOR, RVBD, JIVE, BGFV) (RTTNews)
31.07.13	Amgen Profit Drops On Expenses, But Tops Estimates (RTTNews)
30.07.13	Amgen Q2 Profit Down, But Tops View - Quick Facts (RTTNews)
30.07.13	Amgen's Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89 (PR Newswire)
26.07.13	Amgen Announces 2013 Third Quarter Dividend (PR Newswire)
25.07.13	Amgen Announces Webcast of 2013 Second Quarter Financial Results (PR Newswire)
17.07.13	Reports: Pfizer, Amgen Among Five Potential Suitors For Onyx (RTTNews)
25.07.08	Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial (Businesswire)
14.07.08	Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy (Businesswire)
01.06.08	Updated Data from Ongoing Phase 3 Trials Support the Continued Study of Vectibix(R) (panitumumab) in Combination with Standard Chemotherapy (Businesswire)
28.05.08	Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial versus Weekly Alendronate (FOSAMAX(R)) (Businesswire)
19.05.08	Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study (Businesswire)
16.05.08	Amgen Highlights Data to Be Presented at ASCO (Businesswire)
06.05.08	Amgen to Participate in CHMP Oncology Scientific Advisory Group Meeting in May (Businesswire)
27.01.08	Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy (Businesswire)
15.11.07	Amgen Announces ``My Cancer Coach'' Contest Winners at the College Hoops Classic (Businesswire)
08.11.07	Amgen Announces Updates to the U.S. Prescribing Information for ESAs (Businesswire)
24.10.07	Amgen's Third Quarter 2007 Adjusted Earnings Per Share Increased 4 Percent to $1.08 (Businesswire)
25.09.07	Aranesp(R) DAHANCA 10 Study Results Presented at ECCO Annual Meeting (Businesswire)
21.09.07	Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union (Businesswire)
11.09.07	Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee (Businesswire)
01.08.07	Dennis Fenton, Executive Vice President of Operations, Elects to Retire after 25 Years with Amgen (Businesswire)
01.08.07	Amgen Responds to Final CMS National Coverage Determination on Use of Erythropoiesis-Stimulating Agents in Oncology (Businesswire)
25.05.07	Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab) (Businesswire)
22.05.07	Amgen Names David Lacey, M.D., Senior Vice President, Head of Research (Businesswire)
30.04.07	Final Vectibix(TM) Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published (Businesswire)
19.04.07	Aranesp(R) ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer (Businesswire)
18.04.07	2007 Recipients of Amgen Award for Science Teaching Excellence Announced (Businesswire)
02.03.07	Prime Minister Tony Blair Opens Major Amgen Development Centre in London (Businesswire)
16.01.07	Amgen Launches 2007 Breakaway from Cancer Initiative (Businesswire)
11.12.06	Updated Interim Long-Term Follow-up Data Reported AMG 531 Dosed Once Weekly Increased and Sustained Platelet Counts in Patients with Immune Platelet Disorder (Businesswire)
09.12.06	Data Show Efficacy of Extended Dosing of Aranesp(R) in the Treatment of Chemotherapy-Induced Anemia (Businesswire)
12.11.06	ENBREL is the First Biologic to Publish Data Showing Safety and Sustained Efficacy for up to Nine Years in Patients with Moderate-to-Severe Rheumatoid Arthritis (Businesswire)
04.11.06	AMG 706 Shows Activity in Phase 2 Study of Patients with Advanced Imatinib-Resistant Gastrointestinal Stromal Tumors (Businesswire)
02.11.06	Nominations Open for the Amgen Award for Science Teaching Excellence (Businesswire)
07.09.06	Amgen Launches Aranesp(R) (Darbepoetin Alfa) Prefilled SureClick(TM) Autoinjector for Treatment of Anemia Associated with Chemotherapy and Chronic Kidney Disease (Businesswire)
16.07.06	New Data Demonstrate Benefits of Aranesp(R) Dosed Every Two Weeks in European Haemodialysis Patients With CKD-Related Anaemia (Businesswire)
07.07.06	ITC Judge Grants Summary Determination That Roche's Activities Are Covered by Clinical Trial Exemption; Judge's Decision Does Not Address the Merits of Roche's Infringement of Amgen's Patents (Businesswire)
04.06.06	Phase 2 Interim Data Show Denosumab Decreased Bone Turnover in Advanced Cancer Patients with Bone Metastases (Businesswire)
09.05.06	ITC Accepts Amgen's Complaint to Investigate Roche's Importation of Peg-EPO (Businesswire)
10.04.06	2006 Recipients of Amgen Award for Science Teaching Excellence Announced; 19 Outstanding Science Teachers and Their Schools Recognized in Amgen Communities Across the U.S. and Puerto Rico (Businesswire)
04.04.06	Amgen schliesst Kauf von Abgenix ab; durch den Erwerb wird Panitumumab vollständiges Eigentum von Amgen und eine Denosumab-Lizenzgebührenzahlung entfällt (Businesswire)
22.02.06	Investigational Therapy Denosumab Increased Bone Mineral Density with Twice-Yearly Dosing; One Year Data Published in New England Journal of Medicine (Businesswire)
25.01.06	Amgen investiert umfangreich in Fertigung, Forschung und Entwicklung und den Ausbau des Vertriebs (Businesswire)
14.12.05	Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty (Businesswire)
14.11.05	Treatment Has Demonstrated Improvement in Physical Function and Kept Joint Damage from Progressing at Three Years (Businesswire)
14.11.05	Two-Year Trial Results of Amgen Investigational Therapy for Bone Loss, Denosumab, Show Increased Bone Mineral Density with Twice-Yearly Dosing (Businesswire)
03.11.05	Panitumumab Significantly Improves Progression-Free Survival in Phase 3 Randomized Metastatic Colorectal Cancer Study (Businesswire)
28.10.05	European Commission Approves Kepivance(TM) (Palifermin) for Oral Mucositis in Cancer Patients Undergoing Blood and Bone Marrow Transplant (Businesswire)
19.10.05	Amgen's Third Quarter 2005 Adjusted Earnings Per Share Increased 33 Percent to 85 Cents; Third Quarter 2005 GAAP Earnings Per Share Increased to 77 Cents from 18 Cents (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	535.00	0.75 %	K V
Novartis	92.45	0.57 %	K V
Part Grp Hldg	1’256.50	0.44 %	K V
Holcim	88.80	0.43 %	K V
Kuehne+Nagel Int	209.40	0.38 %	K V
Swiss Life Hldg	717.60	-0.25 %	K V
UBS Group	27.57	-0.68 %	K V
ABB	49.12	-0.85 %	K V
Sika	226.00	-1.14 %	K V
Logitech Intl	70.70	-1.78 %	K V

mehr

15:58		Schwache Performance in Frankfurt: TecDAX zeigt sich nachmittags schwächer
15:58		XETRA-Handel: SDAX am Nachmittag freundlich
15:58		Handel in Europa: So bewegt sich der Euro STOXX 50 aktuell
13:28		Bayer-Analyse: DZ BANK verleiht Bayer-Aktie Kaufen in jüngster Analyse
12:26		XETRA-Handel: SDAX zeigt sich fester
12:26		Schwacher Wochentag in Europa: So performt der Euro STOXX 50 mittags
12:26		Mittwochshandel in Frankfurt: TecDAX gibt am Mittag nach
09:28		Euro STOXX 50 aktuell: Euro STOXX 50 notiert zum Start im Minus

15:58

Schwache Performance in Frankfurt: TecDAX zeigt sich nachmittags schwächer

15:58

XETRA-Handel: SDAX am Nachmittag freundlich

15:58

Handel in Europa: So bewegt sich der Euro STOXX 50 aktuell

13:28

Bayer-Analyse: DZ BANK verleiht Bayer-Aktie Kaufen in jüngster Analyse

12:26

XETRA-Handel: SDAX zeigt sich fester

12:26

Schwacher Wochentag in Europa: So performt der Euro STOXX 50 mittags